Research programme: TNF-alpha inhibitors - Theracos

Drug Profile

Research programme: TNF-alpha inhibitors - Theracos

Alternative Names: CLX-090717; THR-090717

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Calyx Therapeutics (CEASED)
  • Developer Theracos
  • Class Small molecules
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Inflammation; Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (PO)
  • 21 Oct 2009 Pharmacodynamics data from preclinical trials in inflammation presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2009) .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top